DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The "Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages.

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.

The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects.

The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type.

The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics.

Key Topics Covered

Introduction Report Coverage Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type

Companies Mentioned

AbbVie Inc Aclaris Therapeutics Inc Astellas Pharma Inc AstraZeneca Plc Bristol-Myers Squibb Co CJ HealthCare Corp Concert Pharmaceuticals Inc Eli Lilly and Co Galapagos NV Han Wha Pharma Co Ltd Incyte Corp Japan Tobacco Inc Jiangsu Hengrui Medicine Co Ltd LEO Pharma A/S Nissan Chemical Industries Ltd Pfizer Inc Portola Pharmaceuticals Inc Sareum Holdings Plc Theravance Biopharma Inc

For more information about this report visit https://www.researchandmarkets.com/research/d7r48h/a_snapshot_of_the?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005504/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Oncology Drugs,Enzymes

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 04:49 AM/DISC: 06/06/2018 04:49 AM

http://www.businesswire.com/news/home/20180606005504/en